Cirio advises Intervacc on private placement of SEK 147 million

Cirio has advised Intervacc AB (publ) in connection with its private placement of 6.5 million shares directed towards Swedish and international institutional investors. On 16 June 2020, the board of directors resolved on the directed issue authorised by the AGM held on 11 June 2020. The placement generates proceeds of SEK 147 million for the company, before transaction costs. The issue volume and the subscription price were determined by an accelerated book building process.

Intervacc AB (publ) is a company within the biotechnology sector. The company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work. The Intervacc share is listed on Nasdaq First North Growth Market.

Cirio advised Intervacc with a team headed by Per Hedman (M&A/Life sciences) and Maria Arnoldsson (Capital Markets and Public M&A), together with Oscar Lunde and Jesper M. Johansson (Capital Markets and Public M&A).

For more information, please contact: